“We aim to leverage our cross-border culture to rapidly and efficiently deliver new therapies for to patients suffering from liver disease in China and across the globe.”
Erin Quirk, M.D.
Chief Medical Officer
THE TERNS DIFFERENCE
Leveraging an internal drug discovery engine, as well as strategically in-licensed compounds, Terns is developing a portfolio of therapies for the treatment of chronic liver diseases like non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
We are focused on rational combination strategies, targeting the spectrum of chronic liver disease progression, from steatosis to inflammation of the liver, fibrosis and cirrhosis.
There is a staggering need for new therapies in China.
Liver disease is a growing global health burden, particularly for the Chinese population. Our best-in-class drug development team in Shanghai is leading the new wave of NASH innovation in China. We leverage an increasingly flexible regulatory environment, enhanced R&D capabilities and world-class data technology to advance new therapeutics for Chinese patients living with liver disease.
Our portfolio covers the full spectrum of chronic liver disease progression - from non-alcoholic fatty liver disease (NAFLD) and steatosis into non-alcoholic steatohepatitis (NASH): inflammation of the liver and fibrosis.
Research suggests farnesoid X receptor (FXR) agonists like TERN-101 will be the backbone of future combination treatments for NASH. Its broad pleiotropic effect across all stages of disease make it suitable as a primary treatment option. At every stage of disease, there will likely be a need for combination therapy and we are investigating new treatment options for each. This approach differentiates Terns from the many companies developing one or two assets against NAFLD and NASH.